Colorectal Cancer (CRC) Recruiting Phase 2 Trials for Tislelizumab (DB14922)

Back to Colorectal Cancer (CRC)

Also known as: Malignant Neoplasm of Colorectum / CRC, Colorectal Cancer / Colorectal Cancer / Cancer, Colorectal / CRC (Colorectal Cancer) / Colorectal, Cancer / Colo-rectal Cancer / Colorectal Cancers / A. Colorectal Cancer / Cancer Colorectal / Gastrointestinal Cancers - Colorectal / CRC / CRCS / Malignant colorectal neoplasm / Malignant neoplasm of cecum and/or colon and/or rectum / Malignant neoplasm of caecum and/or colon and/or rectum / Malignant neoplasm of cecum and/or colon and/or rectum (disorder) / Malignant neoplasm of large intestine / Malignant tumor of large intestine / Malignant tumour of large intestine / Malignant neoplasm of large intestine (disorder) / Malignant neoplasm of colon, unspecified / Malignant large intestinal neoplasm NOS / Cancer of large intestine / Malignant neoplasm of large intestine, NOS / Cancer of large bowel / CA - Cancer of large bowel / Colorectal neoplasms malignant / Malignant neoplasm of colon and/or rectum (disorder) / Large intestine carcinoma / Colorectal carcinoma / Colorectal cancer NOS

Indication	Status	Phase
DBCOND0031867 (Colorectal Cancer (CRC))	Recruiting	2

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT06722183	Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities	Treatment	Fluorouracil (DB00544) Futibatinib (DB15149) Leucovorin (DB00650) Oxaliplatin (DB00526) Tislelizumab (DB14922)
NCT06529523	Tislelizumab in People With Colorectal Cancer	Treatment	Tislelizumab (DB14922)
NCT05771181	Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients	Treatment	Fruquintinib (DB11679) Tislelizumab (DB14922) Vitamin E (DB00163)